Changes to Primary Endpoints of Cancer Trials Are Not Being Disclosed in Manuscripts
Changes to primary endpoints of phase 3 cancer trials may be common and underreported, a study suggests.
Changes to primary endpoints of phase 3 cancer trials may be common and underreported, a study suggests.
Results of a global survey highlight areas for improvement in the care of patients with renal cell carcinoma.
Pancreatic cancer has proven resistant to immunotherapy in the past, but personalized mRNA vaccines may overcome that problem.
The rising cost of care is having a negative impact on patients with bladder cancer, but a value-based approach to care might provide some relief.
Studies suggest that ctDNA testing has prognostic value in colorectal cancer, but more research is needed before it can be used in practice.
The CAPItello-291, monarchE, RIGHT Choice, and EMERALD trials have shown favorable outcomes for patients with HR+, HER2- breast cancer.
Differences in tumor characteristics could explain sex- and race-based disparities in patients with metastatic non-small cell lung cancer.
As many as 10% of early-onset metastatic colorectal cancer cases may be attributable to undiagnosed inflammatory bowel disease, a study suggests.
Two new studies shed light on the complexity of preventing subsequent breast cancer events in patients with ductal carcinoma in situ.
At a SITC summit, stakeholders identified administrative, staffing, and other barriers that impede progress in clinical cancer research.